Summary:
|
Isotretinoin (Roaccutaneâ–¼): new safety measures to be introduced in the coming months, including additional oversight on initiation of treatment for patients under 18 years. Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality . Nitrofurantoin: reminder of the risks of pulmonary and hepatic adverse drug reactions
|
File Size:
|
345KB
|
Type:
|
Files / Images
|
Created:
|
26 April 2023
|
Last Modified:
|
25 May 2023
|